Zobo plant shows promise against drug-resistant UTI bacteria in Nigerian study

In a laboratory in Katsina State, researchers at the Federal University Dutsin-Ma have begun testing an old remedy against a modern problem. They took Hibiscus sabdariffa—the plant Nigerians know as Zobo, the tart drink served at celebrations and sold on street corners—and asked whether it could fight bacteria that no longer respond to antibiotics.

The question matters because urinary tract infections caused by E. coli have become harder to treat. Antibiotics that once worked reliably now fail. In the study, which examined bacterial samples from patients at a local hospital, researchers found that 80 percent of the E. coli isolates had developed resistance to cefotaxime, a common antibiotic. Seventy percent resisted ciprofloxacin. Sixty percent resisted ampicillin. Four of the ten confirmed cases met the definition of multidrug resistance—meaning the bacteria had learned to survive exposure to at least three different classes of drugs. Only nitrofurantoin, an older medication, still worked reliably against all the isolates tested.

The researchers, led by Mujahid Musa from the Department of Microbiology, collected urine samples from fifty patients suspected of having urinary tract infections. Ten samples tested positive for E. coli, a 20 percent isolation rate. Seven of those ten cases were women, a pattern that holds true globally: women bear a disproportionate burden of these infections, and when the bacteria become resistant, the burden grows heavier.

Then came the laboratory work. The team prepared extracts from the calyces of the Zobo plant using two methods—one with water, one with ethanol. They exposed the resistant bacteria to these extracts and watched what happened. Both preparations inhibited bacterial growth. More intriguingly, as they increased the concentration of the extracts, the antibacterial effect grew stronger. The ethanol extract proved more potent than the aqueous one, suggesting it had extracted the plant's active compounds more effectively. Chemical analysis identified alkaloids, flavonoids, tannins, and saponins in the extracts—compounds known to damage bacterial cell membranes and disrupt the enzyme systems bacteria need to survive.

The findings, published in the Asian Journal of Biotechnology and Genetic Engineering, arrive at a moment when antimicrobial resistance has become what public health experts call one of the world's most serious threats. The problem is not new, but it is accelerating. Misuse of antibiotics and widespread self-medication in many developing countries have accelerated the pace at which bacteria evolve resistance. The cost is measured in treatment failures, longer hospital stays, and rising healthcare expenses.

Yet the researchers were careful with their language. They described Zobo as a "potential complementary antimicrobial agent"—not a cure, not a replacement for antibiotics, but something that might work alongside them. The study was conducted entirely in laboratory conditions, they emphasized. No one drank Zobo and recovered from a resistant infection. No human trials have been conducted. Before the plant can be recommended for actual medical use, much more work lies ahead.

What the findings do offer is something else: evidence that affordable, locally available plant-based solutions might help address a crisis that disproportionately affects countries with limited access to new antibiotics. In resource-limited settings, where the newest drugs are often out of reach, understanding what grows in the garden or the market may matter more than it does elsewhere. The Zobo plant has been used in traditional medicine across Africa, Asia, and the Middle East for generations. Science has now begun to ask why.